- Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients…
Preclinical data shows precision modulation of beta-2 and beta-3 signaling boosts metabolism and enhances body recompositionSTOCKHOLM, Sweden, May 24, 2024…
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting London, 24 May 2024 –…
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;…
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors…
ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response…
— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed — — KB-0742…
– Results from pivotal Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN to be presented in an oral…
- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile…